clinical outcomes of patients with r/r multiple myeloma listed for treatment with car-t therapy
Published 1 year ago • 40 plays • Length 1:47Download video MP4
Download video MP3
Similar videos
-
4:49
factors to predict the outcomes of patients with r/r myeloma treated with car-t therapy
-
0:48
selecting patients with multiple myeloma for car-t therapy
-
2:00
the value of car-t cell therapy for the treatment of r/r multiple myeloma
-
0:55
the significance of cr as an endpoint in frail patients with multiple myeloma
-
0:59
phase i study of cart-ddbcma in r/r multiple myeloma
-
0:50
car-t in multiple myeloma: cilta-cel & ide-cel
-
4:47
phase i study of bb21217 car-t therapy in r/r myeloma
-
4:58
overview of the toxicities associated with bispecific agents in multiple myeloma
-
4:14
challenges with the real-world use of car-t therapy in multiple myeloma
-
5:11
phase i study of phe885 car t-cell therapy in r/r multiple myeloma
-
4:12
car-t therapy in multiple myeloma: recent updates, clinical trials and future outlooks
-
1:01
the potentially curative role of car-t therapy in myeloma
-
0:54
ucartcs1: a novel allogeneic car-t therapy for myeloma
-
1:50
factors to consider when manufacturing car t-cells for patients with r/r multiple myeloma
-
2:22
outpatient management of car-t therapy in multiple myeloma and lymphoma
-
1:12
remission of multiple myeloma with car t-cell therapy
-
0:46
challenges associated with the use of off-the-shelf car-t products in multiple myeloma
-
5:56
advances in car-t therapy for r/r multiple myeloma: ide-cel & cilta-cel
-
2:35
latest advances in car-t for multiple myeloma: cilta-cel & new car-t platforms